Gracell Biotechnologies Inc.

NASDAQ GRCL

Data sourced from

and

Daily

Download Data

Gracell Biotechnologies Inc. Enterprise Value (EV) on February 22, 2024

Gracell Biotechnologies Inc. Enterprise Value (EV) is NA on February 22, 2024, a NA change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.

Gracell Biotechnologies Inc. 52-week high Enterprise Value (EV) is USD 223.71 M on June 13, 2023, which is NA below the current Enterprise Value (EV).
Gracell Biotechnologies Inc. 52-week low Enterprise Value (EV) is USD -89.14 M on April 25, 2023, which is NA below the current Enterprise Value (EV).
Gracell Biotechnologies Inc. average Enterprise Value (EV) for the last 52 weeks is USD 53.90 M.

NASDAQ: GRCL

Gracell Biotechnologies Inc.

CEO	Dr. Wei Cao
IPO Date	Jan. 8, 2021
Location	China
Headquarters	Building 12, Block B, Suzhou, China, 215123
Employees	314
Sector	Healthcare
Industry	Biotechnology

Description

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

Key trends